Dear professor ...


Iím a medical doctor in Ö, specialists in clinical oncology .Regarding the cost-benefit of herceptin and considering limited budget in our country, the health ministry should make decision for to the different subgroups of breast cancer to rescue as many as possible of these patients.



I connect you because you were co responder of this article Ö.Unfortunately I canít find any more article similar to that which reported about the subgroups after 5 years.


Please let me know is there any unpublished article or data about overall survival or disease free survival of any subgroups?

Thanks a lot for the care you take in answering this inquiry.